ImmunityBio, Inc. (IBRX) 10-Year Financial Performance & Capital Metrics

IBRX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.Show more

Revenue $15M +2270.6%
EBITDA -$327M +5.0%
Net Income -$414M +29.1%
EPS (Diluted) -0.62 +46.1%
Gross Margin 100%
EBITDA Margin -2215.18% +96.0%
Operating Margin -2334.23% +96.0%
Net Margin -2804.77% +97.0%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -2.61 +37.4%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 221.4%

✗Weaknesses

✗Negative free cash flow
✗Shares diluted 37.7% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y36.83%

5Y221.39%

3Y150.86%

TTM1025.95%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM40.69%

EPS CAGR

10Y-

5Y-

3Y-

TTM55.33%

ROCE

10Y Avg-116.2%

5Y Avg-175.11%

3Y Avg-153.18%

Latest-88.92%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.26B	9.38	67	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	692.99M	4.09	10.76	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	932.87M	2.35	-1.84	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	630.68M	8.04	-2.62			-117.82%	0.18
IMNMImmunome, Inc.	2.22B	20.14	-4.03	-35.5%	-23.01%	-84.4%	0.03
NKTRNektar Therapeutics	744.1M	36.58	-4.21	9.22%	-192.87%	-141.9%	1.69
IBRXImmunityBio, Inc.	2.78B	2.82	-4.55	22.71%	-422.28%
CRVSCorvus Pharmaceuticals, Inc.	485.43M	6.50	-6.37			-21.01%	0.03

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	236K	44K	45K	47K	43K	605K	934K	240K	622K	14.74M
Revenue Growth %	-0.63%	-0.81%	0.02%	0.04%	-0.09%	13.07%	0.54%	-0.74%	1.59%	22.71%
Cost of Goods Sold+	0	0	0	-3.11M	9.01M	0	0	0	0	0
COGS % of Revenue	-	-	-	-66.17%	209.58%	-	-	-	-	-
Gross Profit+	236K	44K	45K	3.16M	-8.97M	605K	934K	240K	622K	14.74M
Gross Margin %	1%	1%	1%	67.17%	-208.58%	1%	1%	1%	1%	1%
Gross Profit Growth %	-0.63%	-0.81%	0.02%	69.16%	-3.84%	1.07%	0.54%	-0.74%	1.59%	22.71%
Operating Expenses+	237.64M	120.94M	93.6M	88.88M	57.94M	221.49M	331.21M	351.54M	362.87M	358.93M
OpEx % of Revenue	1006.95%	2748.57%	2079.98%	1891.09%	1347.4%	366.09%	354.62%	1464.74%	583.4%	24.34%
Selling, General & Admin	226.21M	94.39M	53.82M	35.46M	9.05M	71.32M	135.26M	102.71M	129.62M	168.78M
SG&A % of Revenue	958.5%	2145.25%	1196.02%	754.53%	210.53%	117.88%	144.81%	427.95%	208.39%	11.45%
Research & Development	11.43M	26.55M	39.78M	53.42M	48.88M	139.51M	195.96M	248.15M	232.37M	190.14M
R&D % of Revenue	48.45%	603.32%	883.96%	1136.55%	1136.86%	230.59%	209.81%	1033.95%	373.58%	12.9%
Other Operating Expenses	0	0	0	0	0	10.66M	0	681K	886K	0
Operating Income+	-238.88M	-124.5M	-99.12M	-98.39M	-66.91M	-220.88M	-330.28M	-351.3M	-362.25M	-344.18M
Operating Margin %	-1012.19%	-2829.55%	-2202.67%	-2093.38%	-1555.98%	-365.09%	-353.62%	-1463.74%	-582.4%	-23.34%
Operating Income Growth %	-37.45%	0.48%	0.2%	0.01%	0.32%	-2.3%	-0.5%	-0.06%	-0.03%	0.05%
EBITDA+	-237.4M	-120.89M	-93.55M	-88.83M	-57.9M	-208.14M	-316.04M	-333.04M	-343.74M	-326.63M
EBITDA Margin %	-1005.95%	-2747.57%	-2078.98%	-1890.09%	-1346.4%	-344.03%	-338.37%	-1387.66%	-552.63%	-22.15%
EBITDA Growth %	-38.02%	0.49%	0.23%	0.05%	0.35%	-2.6%	-0.52%	-0.05%	-0.03%	0.05%
D&A (Non-Cash Add-back)	1.47M	3.61M	5.57M	9.55M	9.01M	12.74M	14.24M	18.26M	18.51M	17.55M
EBIT	-237.18M	-121.31M	-96.3M	-96.3M	-65.87M	-216.96M	-334.99M	-370.14M	-497.18M	-281.99M
Net Interest Income+	0	0	0	0	-3.16M	-7.35M	-14.01M	-44.44M	-85.85M	-129.26M
Interest Income	0	0	0	0	2.76M	1.73M	836K	2.71M	863K	2.4M
Interest Expense	0	66K	618K	433K	5.92M	9.07M	14.85M	47.15M	86.72M	131.66M
Other Income/Expense	1.7M	3.12M	2.2M	1.66M	1.02M	-5.15M	-19.56M	-65.99M	-221.64M	-69.46M
Pretax Income+	-237.18M	-121.38M	-96.92M	-96.73M	-65.89M	-226.03M	-349.84M	-417.29M	-583.89M	-413.64M
Pretax Margin %	-1004.99%	-2758.66%	-2153.69%	-2058.06%	-1532.23%	-373.61%	-374.56%	-1738.69%	-938.73%	-28.05%
Income Tax+	-301K	-572K	-493K	-503K	-97K	-1.85M	9K	34K	-40K	0
Effective Tax Rate %	1%	1%	0.99%	0.99%	1%	0.98%	0.99%	1%	1%	1%
Net Income+	-236.88M	-120.81M	-96.42M	-96.23M	-65.79M	-221.85M	-346.79M	-416.57M	-583.2M	-413.56M
Net Margin %	-1003.71%	-2745.66%	-2142.73%	-2047.36%	-1529.98%	-366.7%	-371.3%	-1735.7%	-937.61%	-28.05%
Net Income Growth %	-37.13%	0.49%	0.2%	0%	0.32%	-2.37%	-0.56%	-0.2%	-0.4%	0.29%
Net Income (Continuing)	-236.88M	-120.81M	-96.42M	-96.23M	-65.79M	-224.19M	-349.85M	-417.32M	-583.85M	-413.64M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	-12.32M	0	1.32M	-1.74M	-2.49M	1.05M	969K
EPS (Diluted)+	-0.73	-0.37	-0.30	-0.30	-0.42	-0.59	-0.89	-1.04	-1.15	-0.62
EPS Growth %	-36.06%	0.49%	0.19%	0%	-0.4%	-0.4%	-0.51%	-0.17%	-0.11%	0.46%
EPS (Basic)	-0.73	-0.37	-0.30	-0.30	-0.42	-0.59	-0.89	-1.04	-1.15	-0.59
Diluted Shares Outstanding	326.3M	328.55M	316.15M	325.05M	383.18M	383.18M	389.23M	399.9M	508.64M	700.44M
Basic Shares Outstanding	326.3M	328.55M	316.15M	325.05M	383.18M	383.18M	389.23M	399.9M	508.64M	697.31M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	297.54M	205.15M	132.46M	88.77M	55.76M	111.71M	334.35M	140.58M	294.08M	184.59M
Cash & Short-Term Investments	294.22M	198.92M	128.15M	74.15M	51.65M	96.06M	317.12M	107.18M	266.46M	149.81M
Cash Only	175.91M	8.08M	23.87M	16.82M	15.51M	34.91M	181.1M	104.64M	265.45M	143.43M
Short-Term Investments	118.31M	190.84M	104.28M	57.33M	36.14M	61.15M	136.01M	2.54M	1.01M	6.38M
Accounts Receivable	1.77M	0	1.26M	12.17M	303K	2M	1.33M	1.89M	3.17M	2.65M
Days Sales Outstanding	2.74K	-	10.2K	94.5K	2.57K	1.21K	520.93	2.87K	1.86K	65.67
Inventory	0	0	0	0	0	0	0	0	0	8.27M
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	662K	880K	42K	24K	0	2.96M	2.9M	5.21M	1.3M
Total Non-Current Assets+	69.31M	112.35M	117.98M	93.18M	87.37M	109.67M	134.56M	221.78M	210.37M	198.35M
Property, Plant & Equipment	6.15M	19.27M	76.73M	76.89M	72.23M	90.68M	119.17M	189.45M	182.68M	170.46M
Fixed Asset Turnover	0.04x	0.00x	0.00x	0.00x	0.00x	0.01x	0.01x	0.00x	0.00x	0.09x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	7.29M	5.09M	2.83M	12.09M	0	1.46M	1.42M	20M	17.09M	15.93M
Long-Term Investments	55.13M	87.75M	38.28M	14.38M	10.93M	11.4M	7.6M	840K	891K	0
Other Non-Current Assets	344K	137K	151K	-1.67M	4.21M	6.13M	6.38M	11.49M	9.7M	11.96M
Total Assets+	366.85M	317.5M	250.44M	181.95M	143.12M	221.38M	468.91M	362.36M	504.45M	382.93M
Asset Turnover	0.00x	0.00x	0.00x	0.00x	0.00x	0.00x	0.00x	0.00x	0.00x	0.04x
Asset Growth %	5.03%	-0.13%	-0.21%	-0.27%	-0.21%	0.55%	1.12%	-0.23%	0.39%	-0.24%
Total Current Liabilities+	6.15M	12.55M	20.87M	27.26M	11.56M	68.13M	369M	500.86M	58.28M	54.94M
Accounts Payable	2.08M	4.04M	5.87M	2.79M	1.75M	11.51M	11.42M	21.02M	9.2M	6.72M
Days Payables Outstanding	-	-	-	-327.8	70.84	-	-	-	-	-
Short-Term Debt	-228K	534K	618K	965K	3.96M	0	299.24M	431.9M	0	0
Deferred Revenue (Current)	228K	197K	520K	0	0	0	0	0	0	0
Other Current Liabilities	4.06M	7.78M	13.87M	23.5M	4.78M	18M	16.52M	19.74M	18.31M	15.98M
Current Ratio	48.40x	16.34x	6.35x	3.26x	4.82x	1.64x	0.91x	0.28x	5.05x	3.36x
Quick Ratio	48.40x	16.34x	6.35x	3.26x	4.82x	1.64x	0.91x	0.28x	5.05x	3.21x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	4.71M	11.53M	10.73M	8.68M	10.88M	271.74M	343.83M	311.31M	1.03B	816.12M
Long-Term Debt	2.47M	0	0	0	0	254.35M	306.35M	241.27M	681.54M	461.88M
Capital Lease Obligations	2.47M	7.68M	6.65M	5.95M	10.88M	16.18M	37.07M	47.95M	39.94M	34.82M
Deferred Tax Liabilities	1.17M	996K	498K	0	0	170K	162K	0	0	0
Other Non-Current Liabilities	-1.4M	2.67M	3.41M	2.74M	0	1.03M	249K	22.09M	310.63M	319.42M
Total Liabilities	10.85M	24.08M	31.6M	35.94M	22.44M	339.87M	712.82M	812.18M	1.09B	871.06M
Total Debt+	2.47M	8.21M	7.27M	6.91M	14.85M	275.55M	645.66M	723.77M	726.72M	504.17M
Net Debt	-173.44M	127K	-16.6M	-9.91M	-660K	240.63M	464.56M	619.13M	461.27M	360.74M
Debt / Equity	0.01x	0.03x	0.03x	0.05x	0.12x	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-1886.36x	-160.39x	-227.23x	-11.30x	-24.34x	-22.24x	-7.45x	-4.18x	-2.61x
Total Equity+	356M	293.42M	218.84M	133.69M	120.68M	-118.49M	-243.91M	-449.82M	-585.94M	-488.13M
Equity Growth %	5.09%	-0.18%	-0.25%	-0.39%	-0.1%	-1.98%	-1.06%	-0.84%	-0.3%	0.17%
Book Value per Share	1.09	0.89	0.69	0.41	0.31	-0.31	-0.63	-1.12	-1.15	-0.70
Total Shareholders' Equity	356M	293.42M	218.84M	146.01M	120.68M	-119.81M	-242.17M	-447.33M	-586.99M	-489.1M
Common Stock	8K	8K	8K	8K	10K	38K	40K	42K	67K	85K
Retained Earnings	-250.38M	-387.06M	-498.71M	-594.98M	-662.19M	-1.62B	-1.96B	-2.38B	-2.96B	-3.38B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-192K	-284K	-381K	-267K	-105K	122K	4K	183K	10K	1.2M
Minority Interest	0	0	0	-12.32M	0	1.32M	-1.74M	-2.49M	1.05M	969K

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-25.3M	-38.59M	-48.78M	-63.38M	-152.11M	-171.72M	-274.42M	-337.51M	-366.76M	-391.24M
Operating CF Margin %	-107.22%	-877.11%	-1084%	-1348.53%	-3537.42%	-283.84%	-293.81%	-1406.29%	-589.64%	-26.53%
Operating CF Growth %	-3.73%	-0.53%	-0.26%	-0.3%	-1.4%	-0.13%	-0.6%	-0.23%	-0.09%	-0.07%
Net Income	-236.88M	-120.81M	-96.42M	-96.23M	-160.16M	-224.19M	-346.79M	-416.57M	-583.85M	-413.64M
Depreciation & Amortization	1.47M	3.61M	5.57M	9.55M	14.04M	12.74M	14.3M	34.54M	18.51M	17.55M
Stock-Based Compensation	211.22M	73.85M	37M	2.04M	3.42M	2.19M	57.18M	40.18M	49.16M	34.43M
Deferred Taxes	-302K	-575K	-497K	-498K	-8K	-2.94M	0	0	0	0
Other Non-Cash Items	212.36M	81.67M	50.33M	44.55M	6.23M	24.11M	16.29M	20.34M	145.44M	-10.15M
Working Capital Changes	282K	3.84M	3.23M	-554K	-15.64M	16.36M	-15.39M	-16M	3.98M	-19.42M
Change in Receivables	75K	-1.46M	0	0	0	0	0	0	0	-2.36M
Change in Inventory	0	0	0	0	0	0	0	0	0	-8.27M
Change in Payables	627K	888K	150K	-1.1M	1.19M	2.57M	0	0	-6.48M	-3.17M
Cash from Investing+	-175.22M	-113.67M	99.55M	57.1M	18.55M	-19.81M	-84.89M	27.3M	-30.47M	-12.25M
Capital Expenditures	-2.24M	-6.56M	-34.81M	-13.1M	-4.29M	-1.67M	-33.56M	-78.16M	-30.58M	-6.89M
CapEx % of Revenue	9.5%	149.09%	773.67%	278.77%	99.7%	2.76%	35.93%	325.68%	49.17%	0.47%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-1.82M	137K	32K	35.03M	-2.5M	-8K	-51.32M	105.46M	0	-747K
Cash from Financing+	317.33M	-15.56M	-34.98M	-771K	114.28M	150.68M	505.44M	233.61M	558.34M	281.63M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-2.42M	-1.11M	-1.04M	-123K	39.11M	673K	171.01M	60.16M	189.62M	73.38M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-27.55M	-45.15M	-83.59M	-76.48M	-156.4M	-173.39M	-307.98M	-415.67M	-397.34M	-398.12M
FCF Margin %	-116.72%	-1026.2%	-1857.67%	-1627.3%	-3637.12%	-286.6%	-329.75%	-1731.96%	-638.81%	-27%
FCF Growth %	-3.87%	-0.64%	-0.85%	0.09%	-1.04%	-0.11%	-0.78%	-0.35%	0.04%	-0%
FCF per Share	-0.08	-0.14	-0.26	-0.24	-0.41	-0.45	-0.79	-1.04	-0.78	-0.57
FCF Conversion (FCF/Net Income)	0.11x	0.32x	0.51x	0.66x	2.31x	0.77x	0.79x	0.81x	0.63x	0.95x
Interest Paid	0	0	0	0	19K	40K	2.11M	35.44M	77.19M	92.32M
Taxes Paid	0	0	0	0	3K	8K	0	0	8K	15K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-114.32%	-37.21%	-37.65%	-54.59%	-51.73%	-20269.62%	-	-	-	-
Return on Invested Capital (ROIC)	-196.73%	-39.23%	-29.99%	-45.27%	-41.17%	-136.82%	-144.53%	-135.13%	-1217.1%	-
Gross Margin	100%	100%	100%	6717.02%	-20858.14%	100%	100%	100%	100%	100%
Net Margin	-100371.19%	-274565.91%	-214273.33%	-204736.17%	-152997.67%	-36669.59%	-37129.55%	-173569.58%	-93761.41%	-2804.77%
Debt / Equity	0.01x	0.03x	0.03x	0.05x	0.12x	-	-	-	-	-
Interest Coverage	-	-1886.36x	-160.39x	-227.23x	-11.30x	-24.34x	-22.24x	-7.45x	-4.18x	-2.61x
FCF Conversion	0.11x	0.32x	0.51x	0.66x	2.31x	0.77x	0.79x	0.81x	0.63x	0.95x
Revenue Growth	-63.18%	-81.36%	2.27%	4.44%	-8.51%	1306.98%	54.38%	-74.3%	159.17%	2270.58%

Revenue by Segment

	2015	2016	2017	2021	2022	2023	2024
Product	-	-	-	-	-	-	14.15M
Product Growth	-	-	-	-	-	-	-
Product and Service, Other	-	-	-	-	-	-	595K
Product and Service, Other Growth	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2021	2022	2023	2024
UNITED STATES	-	44K	45K	373K	42K	31K	14.21M
UNITED STATES Growth	-	-	2.27%	728.89%	-88.74%	-26.19%	45751.61%
Europe	21K	-	-	561K	198K	591K	531K
Europe Growth	-	-	-	-	-64.71%	198.48%	-10.15%
Non Us	24K	-	-	-	-	-	-
Non Us Growth	-	-	-	-	-	-	-
U S	191K	-	-	-	-	-	-
U S Growth	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

ImmunityBio, Inc. (IBRX) reported $82.6M in revenue for fiscal year 2024. This represents a 13659% increase from $0.6M in 2013.

ImmunityBio, Inc. (IBRX) grew revenue by 2270.6% over the past year. This is strong growth.

ImmunityBio, Inc. (IBRX) reported a net loss of $348.6M for fiscal year 2024.

Dividend & Returns

ImmunityBio, Inc. (IBRX) had negative free cash flow of $324.0M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

ImmunityBio, Inc. (IBRX) 10-Year Financial Performance & Capital Metrics

IBRX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

Revenue $15M +2270.6%
EBITDA -$327M +5.0%
Net Income -$414M +29.1%
EPS (Diluted) -0.62 +46.1%
Gross Margin 100%
EBITDA Margin -2215.18% +96.0%
Operating Margin -2334.23% +96.0%
Net Margin -2804.77% +97.0%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -2.61 +37.4%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 221.4%

✗Weaknesses

✗Negative free cash flow
✗Shares diluted 37.7% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y36.83%

5Y221.39%

3Y150.86%

TTM1025.95%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM40.69%

EPS CAGR

10Y-

5Y-

3Y-

TTM55.33%

ROCE

10Y Avg-116.2%

5Y Avg-175.11%

3Y Avg-153.18%

Latest-88.92%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.26B	9.38	67	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	692.99M	4.09	10.76	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	932.87M	2.35	-1.84	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	630.68M	8.04	-2.62			-117.82%	0.18
IMNMImmunome, Inc.	2.22B	20.14	-4.03	-35.5%	-23.01%	-84.4%	0.03
NKTRNektar Therapeutics	744.1M	36.58	-4.21	9.22%	-192.87%	-141.9%	1.69
IBRXImmunityBio, Inc.	2.78B	2.82	-4.55	22.71%	-422.28%
CRVSCorvus Pharmaceuticals, Inc.	485.43M	6.50	-6.37			-21.01%	0.03

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	236K	44K	45K	47K	43K	605K	934K	240K	622K	14.74M
Revenue Growth %	-0.63%	-0.81%	0.02%	0.04%	-0.09%	13.07%	0.54%	-0.74%	1.59%	22.71%
Cost of Goods Sold+	0	0	0	-3.11M	9.01M	0	0	0	0	0
COGS % of Revenue	-	-	-	-66.17%	209.58%	-	-	-	-	-
Gross Profit+	236K	44K	45K	3.16M	-8.97M	605K	934K	240K	622K	14.74M
Gross Margin %	1%	1%	1%	67.17%	-208.58%	1%	1%	1%	1%	1%
Gross Profit Growth %	-0.63%	-0.81%	0.02%	69.16%	-3.84%	1.07%	0.54%	-0.74%	1.59%	22.71%
Operating Expenses+	237.64M	120.94M	93.6M	88.88M	57.94M	221.49M	331.21M	351.54M	362.87M	358.93M
OpEx % of Revenue	1006.95%	2748.57%	2079.98%	1891.09%	1347.4%	366.09%	354.62%	1464.74%	583.4%	24.34%
Selling, General & Admin	226.21M	94.39M	53.82M	35.46M	9.05M	71.32M	135.26M	102.71M	129.62M	168.78M
SG&A % of Revenue	958.5%	2145.25%	1196.02%	754.53%	210.53%	117.88%	144.81%	427.95%	208.39%	11.45%
Research & Development	11.43M	26.55M	39.78M	53.42M	48.88M	139.51M	195.96M	248.15M	232.37M	190.14M
R&D % of Revenue	48.45%	603.32%	883.96%	1136.55%	1136.86%	230.59%	209.81%	1033.95%	373.58%	12.9%
Other Operating Expenses	0	0	0	0	0	10.66M	0	681K	886K	0
Operating Income+	-238.88M	-124.5M	-99.12M	-98.39M	-66.91M	-220.88M	-330.28M	-351.3M	-362.25M	-344.18M
Operating Margin %	-1012.19%	-2829.55%	-2202.67%	-2093.38%	-1555.98%	-365.09%	-353.62%	-1463.74%	-582.4%	-23.34%
Operating Income Growth %	-37.45%	0.48%	0.2%	0.01%	0.32%	-2.3%	-0.5%	-0.06%	-0.03%	0.05%
EBITDA+	-237.4M	-120.89M	-93.55M	-88.83M	-57.9M	-208.14M	-316.04M	-333.04M	-343.74M	-326.63M
EBITDA Margin %	-1005.95%	-2747.57%	-2078.98%	-1890.09%	-1346.4%	-344.03%	-338.37%	-1387.66%	-552.63%	-22.15%
EBITDA Growth %	-38.02%	0.49%	0.23%	0.05%	0.35%	-2.6%	-0.52%	-0.05%	-0.03%	0.05%
D&A (Non-Cash Add-back)	1.47M	3.61M	5.57M	9.55M	9.01M	12.74M	14.24M	18.26M	18.51M	17.55M
EBIT	-237.18M	-121.31M	-96.3M	-96.3M	-65.87M	-216.96M	-334.99M	-370.14M	-497.18M	-281.99M
Net Interest Income+	0	0	0	0	-3.16M	-7.35M	-14.01M	-44.44M	-85.85M	-129.26M
Interest Income	0	0	0	0	2.76M	1.73M	836K	2.71M	863K	2.4M
Interest Expense	0	66K	618K	433K	5.92M	9.07M	14.85M	47.15M	86.72M	131.66M
Other Income/Expense	1.7M	3.12M	2.2M	1.66M	1.02M	-5.15M	-19.56M	-65.99M	-221.64M	-69.46M
Pretax Income+	-237.18M	-121.38M	-96.92M	-96.73M	-65.89M	-226.03M	-349.84M	-417.29M	-583.89M	-413.64M
Pretax Margin %	-1004.99%	-2758.66%	-2153.69%	-2058.06%	-1532.23%	-373.61%	-374.56%	-1738.69%	-938.73%	-28.05%
Income Tax+	-301K	-572K	-493K	-503K	-97K	-1.85M	9K	34K	-40K	0
Effective Tax Rate %	1%	1%	0.99%	0.99%	1%	0.98%	0.99%	1%	1%	1%
Net Income+	-236.88M	-120.81M	-96.42M	-96.23M	-65.79M	-221.85M	-346.79M	-416.57M	-583.2M	-413.56M
Net Margin %	-1003.71%	-2745.66%	-2142.73%	-2047.36%	-1529.98%	-366.7%	-371.3%	-1735.7%	-937.61%	-28.05%
Net Income Growth %	-37.13%	0.49%	0.2%	0%	0.32%	-2.37%	-0.56%	-0.2%	-0.4%	0.29%
Net Income (Continuing)	-236.88M	-120.81M	-96.42M	-96.23M	-65.79M	-224.19M	-349.85M	-417.32M	-583.85M	-413.64M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	-12.32M	0	1.32M	-1.74M	-2.49M	1.05M	969K
EPS (Diluted)+	-0.73	-0.37	-0.30	-0.30	-0.42	-0.59	-0.89	-1.04	-1.15	-0.62
EPS Growth %	-36.06%	0.49%	0.19%	0%	-0.4%	-0.4%	-0.51%	-0.17%	-0.11%	0.46%
EPS (Basic)	-0.73	-0.37	-0.30	-0.30	-0.42	-0.59	-0.89	-1.04	-1.15	-0.59
Diluted Shares Outstanding	326.3M	328.55M	316.15M	325.05M	383.18M	383.18M	389.23M	399.9M	508.64M	700.44M
Basic Shares Outstanding	326.3M	328.55M	316.15M	325.05M	383.18M	383.18M	389.23M	399.9M	508.64M	697.31M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	297.54M	205.15M	132.46M	88.77M	55.76M	111.71M	334.35M	140.58M	294.08M	184.59M
Cash & Short-Term Investments	294.22M	198.92M	128.15M	74.15M	51.65M	96.06M	317.12M	107.18M	266.46M	149.81M
Cash Only	175.91M	8.08M	23.87M	16.82M	15.51M	34.91M	181.1M	104.64M	265.45M	143.43M
Short-Term Investments	118.31M	190.84M	104.28M	57.33M	36.14M	61.15M	136.01M	2.54M	1.01M	6.38M
Accounts Receivable	1.77M	0	1.26M	12.17M	303K	2M	1.33M	1.89M	3.17M	2.65M
Days Sales Outstanding	2.74K	-	10.2K	94.5K	2.57K	1.21K	520.93	2.87K	1.86K	65.67
Inventory	0	0	0	0	0	0	0	0	0	8.27M
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	662K	880K	42K	24K	0	2.96M	2.9M	5.21M	1.3M
Total Non-Current Assets+	69.31M	112.35M	117.98M	93.18M	87.37M	109.67M	134.56M	221.78M	210.37M	198.35M
Property, Plant & Equipment	6.15M	19.27M	76.73M	76.89M	72.23M	90.68M	119.17M	189.45M	182.68M	170.46M
Fixed Asset Turnover	0.04x	0.00x	0.00x	0.00x	0.00x	0.01x	0.01x	0.00x	0.00x	0.09x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	7.29M	5.09M	2.83M	12.09M	0	1.46M	1.42M	20M	17.09M	15.93M
Long-Term Investments	55.13M	87.75M	38.28M	14.38M	10.93M	11.4M	7.6M	840K	891K	0
Other Non-Current Assets	344K	137K	151K	-1.67M	4.21M	6.13M	6.38M	11.49M	9.7M	11.96M
Total Assets+	366.85M	317.5M	250.44M	181.95M	143.12M	221.38M	468.91M	362.36M	504.45M	382.93M
Asset Turnover	0.00x	0.00x	0.00x	0.00x	0.00x	0.00x	0.00x	0.00x	0.00x	0.04x
Asset Growth %	5.03%	-0.13%	-0.21%	-0.27%	-0.21%	0.55%	1.12%	-0.23%	0.39%	-0.24%
Total Current Liabilities+	6.15M	12.55M	20.87M	27.26M	11.56M	68.13M	369M	500.86M	58.28M	54.94M
Accounts Payable	2.08M	4.04M	5.87M	2.79M	1.75M	11.51M	11.42M	21.02M	9.2M	6.72M
Days Payables Outstanding	-	-	-	-327.8	70.84	-	-	-	-	-
Short-Term Debt	-228K	534K	618K	965K	3.96M	0	299.24M	431.9M	0	0
Deferred Revenue (Current)	228K	197K	520K	0	0	0	0	0	0	0
Other Current Liabilities	4.06M	7.78M	13.87M	23.5M	4.78M	18M	16.52M	19.74M	18.31M	15.98M
Current Ratio	48.40x	16.34x	6.35x	3.26x	4.82x	1.64x	0.91x	0.28x	5.05x	3.36x
Quick Ratio	48.40x	16.34x	6.35x	3.26x	4.82x	1.64x	0.91x	0.28x	5.05x	3.21x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	4.71M	11.53M	10.73M	8.68M	10.88M	271.74M	343.83M	311.31M	1.03B	816.12M
Long-Term Debt	2.47M	0	0	0	0	254.35M	306.35M	241.27M	681.54M	461.88M
Capital Lease Obligations	2.47M	7.68M	6.65M	5.95M	10.88M	16.18M	37.07M	47.95M	39.94M	34.82M
Deferred Tax Liabilities	1.17M	996K	498K	0	0	170K	162K	0	0	0
Other Non-Current Liabilities	-1.4M	2.67M	3.41M	2.74M	0	1.03M	249K	22.09M	310.63M	319.42M
Total Liabilities	10.85M	24.08M	31.6M	35.94M	22.44M	339.87M	712.82M	812.18M	1.09B	871.06M
Total Debt+	2.47M	8.21M	7.27M	6.91M	14.85M	275.55M	645.66M	723.77M	726.72M	504.17M
Net Debt	-173.44M	127K	-16.6M	-9.91M	-660K	240.63M	464.56M	619.13M	461.27M	360.74M
Debt / Equity	0.01x	0.03x	0.03x	0.05x	0.12x	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-1886.36x	-160.39x	-227.23x	-11.30x	-24.34x	-22.24x	-7.45x	-4.18x	-2.61x
Total Equity+	356M	293.42M	218.84M	133.69M	120.68M	-118.49M	-243.91M	-449.82M	-585.94M	-488.13M
Equity Growth %	5.09%	-0.18%	-0.25%	-0.39%	-0.1%	-1.98%	-1.06%	-0.84%	-0.3%	0.17%
Book Value per Share	1.09	0.89	0.69	0.41	0.31	-0.31	-0.63	-1.12	-1.15	-0.70
Total Shareholders' Equity	356M	293.42M	218.84M	146.01M	120.68M	-119.81M	-242.17M	-447.33M	-586.99M	-489.1M
Common Stock	8K	8K	8K	8K	10K	38K	40K	42K	67K	85K
Retained Earnings	-250.38M	-387.06M	-498.71M	-594.98M	-662.19M	-1.62B	-1.96B	-2.38B	-2.96B	-3.38B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-192K	-284K	-381K	-267K	-105K	122K	4K	183K	10K	1.2M
Minority Interest	0	0	0	-12.32M	0	1.32M	-1.74M	-2.49M	1.05M	969K

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-25.3M	-38.59M	-48.78M	-63.38M	-152.11M	-171.72M	-274.42M	-337.51M	-366.76M	-391.24M
Operating CF Margin %	-107.22%	-877.11%	-1084%	-1348.53%	-3537.42%	-283.84%	-293.81%	-1406.29%	-589.64%	-26.53%
Operating CF Growth %	-3.73%	-0.53%	-0.26%	-0.3%	-1.4%	-0.13%	-0.6%	-0.23%	-0.09%	-0.07%
Net Income	-236.88M	-120.81M	-96.42M	-96.23M	-160.16M	-224.19M	-346.79M	-416.57M	-583.85M	-413.64M
Depreciation & Amortization	1.47M	3.61M	5.57M	9.55M	14.04M	12.74M	14.3M	34.54M	18.51M	17.55M
Stock-Based Compensation	211.22M	73.85M	37M	2.04M	3.42M	2.19M	57.18M	40.18M	49.16M	34.43M
Deferred Taxes	-302K	-575K	-497K	-498K	-8K	-2.94M	0	0	0	0
Other Non-Cash Items	212.36M	81.67M	50.33M	44.55M	6.23M	24.11M	16.29M	20.34M	145.44M	-10.15M
Working Capital Changes	282K	3.84M	3.23M	-554K	-15.64M	16.36M	-15.39M	-16M	3.98M	-19.42M
Change in Receivables	75K	-1.46M	0	0	0	0	0	0	0	-2.36M
Change in Inventory	0	0	0	0	0	0	0	0	0	-8.27M
Change in Payables	627K	888K	150K	-1.1M	1.19M	2.57M	0	0	-6.48M	-3.17M
Cash from Investing+	-175.22M	-113.67M	99.55M	57.1M	18.55M	-19.81M	-84.89M	27.3M	-30.47M	-12.25M
Capital Expenditures	-2.24M	-6.56M	-34.81M	-13.1M	-4.29M	-1.67M	-33.56M	-78.16M	-30.58M	-6.89M
CapEx % of Revenue	9.5%	149.09%	773.67%	278.77%	99.7%	2.76%	35.93%	325.68%	49.17%	0.47%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-1.82M	137K	32K	35.03M	-2.5M	-8K	-51.32M	105.46M	0	-747K
Cash from Financing+	317.33M	-15.56M	-34.98M	-771K	114.28M	150.68M	505.44M	233.61M	558.34M	281.63M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-2.42M	-1.11M	-1.04M	-123K	39.11M	673K	171.01M	60.16M	189.62M	73.38M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-27.55M	-45.15M	-83.59M	-76.48M	-156.4M	-173.39M	-307.98M	-415.67M	-397.34M	-398.12M
FCF Margin %	-116.72%	-1026.2%	-1857.67%	-1627.3%	-3637.12%	-286.6%	-329.75%	-1731.96%	-638.81%	-27%
FCF Growth %	-3.87%	-0.64%	-0.85%	0.09%	-1.04%	-0.11%	-0.78%	-0.35%	0.04%	-0%
FCF per Share	-0.08	-0.14	-0.26	-0.24	-0.41	-0.45	-0.79	-1.04	-0.78	-0.57
FCF Conversion (FCF/Net Income)	0.11x	0.32x	0.51x	0.66x	2.31x	0.77x	0.79x	0.81x	0.63x	0.95x
Interest Paid	0	0	0	0	19K	40K	2.11M	35.44M	77.19M	92.32M
Taxes Paid	0	0	0	0	3K	8K	0	0	8K	15K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-114.32%	-37.21%	-37.65%	-54.59%	-51.73%	-20269.62%	-	-	-	-
Return on Invested Capital (ROIC)	-196.73%	-39.23%	-29.99%	-45.27%	-41.17%	-136.82%	-144.53%	-135.13%	-1217.1%	-
Gross Margin	100%	100%	100%	6717.02%	-20858.14%	100%	100%	100%	100%	100%
Net Margin	-100371.19%	-274565.91%	-214273.33%	-204736.17%	-152997.67%	-36669.59%	-37129.55%	-173569.58%	-93761.41%	-2804.77%
Debt / Equity	0.01x	0.03x	0.03x	0.05x	0.12x	-	-	-	-	-
Interest Coverage	-	-1886.36x	-160.39x	-227.23x	-11.30x	-24.34x	-22.24x	-7.45x	-4.18x	-2.61x
FCF Conversion	0.11x	0.32x	0.51x	0.66x	2.31x	0.77x	0.79x	0.81x	0.63x	0.95x
Revenue Growth	-63.18%	-81.36%	2.27%	4.44%	-8.51%	1306.98%	54.38%	-74.3%	159.17%	2270.58%

Revenue by Segment

	2015	2016	2017	2021	2022	2023	2024
Product	-	-	-	-	-	-	14.15M
Product Growth	-	-	-	-	-	-	-
Product and Service, Other	-	-	-	-	-	-	595K
Product and Service, Other Growth	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2021	2022	2023	2024
UNITED STATES	-	44K	45K	373K	42K	31K	14.21M
UNITED STATES Growth	-	-	2.27%	728.89%	-88.74%	-26.19%	45751.61%
Europe	21K	-	-	561K	198K	591K	531K
Europe Growth	-	-	-	-	-64.71%	198.48%	-10.15%
Non Us	24K	-	-	-	-	-	-
Non Us Growth	-	-	-	-	-	-	-
U S	191K	-	-	-	-	-	-
U S Growth	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

ImmunityBio, Inc. (IBRX) reported $82.6M in revenue for fiscal year 2024. This represents a 13659% increase from $0.6M in 2013.

ImmunityBio, Inc. (IBRX) grew revenue by 2270.6% over the past year. This is strong growth.

ImmunityBio, Inc. (IBRX) reported a net loss of $348.6M for fiscal year 2024.

Dividend & Returns

ImmunityBio, Inc. (IBRX) had negative free cash flow of $324.0M in fiscal year 2024, likely due to heavy capital investments.